Design of Novel Antagonists for BACE1 Enzyme: An approach to targeting Alzheimer’s Disease

Vol 4, 2026 - 345247
Abstract
Favorite this paper
How to cite this paper?
Abstract

Alzheimer's disease (AD), the most prevalent form of dementia worldwide, has consolidated itself as a public health challenge aggravated by population aging. Although the exact cause of the disease remains unknown, the Amyloid Cascade Hypothesis highlights the central role of amyloid-beta (Aβ) peptide accumulation and aggregation in neurodegenerative process. However, current pharmacological therapies offer only symptomatic relief to the patient, without delaying disease progression. Since Aβ fragments result from the cleavage of the Amyloid Precursor Protein (APP) by the enzyme beta-secretase 1 (BACE1), targeting its catalytic site with inhibitors emerges as a promising strategy for the development of new therapeutic alternatives. Nevertheless, BACE1 extensive catalytic site and its high structural similarity to other aspartic proteases, such as BACE2, represent challenges for the selectivity of synthetic inhibitors, hindering their action on the target. In this landscape, the use of computational modeling techniques constitutes an effective approach in the investigation of enzyme-ligand interaction. The present study employed in silico strategies to evaluate the potential of phenolic compounds from yerba mate (Ilex paraguariensis), associated with neuroprotective properties, to act as BACE1 antagonists. For this purpose, four crystallographic structures of this protein (PDB IDs: 5MCQ, 5MCO, 3K5G, and 4DPI), taken from the Protein Data Bank (PDB/RCSB), were prepared, modeled, equilibrated under NVT and NPT ensembles, and subjected to 200 nanoseconds of molecular dynamics simulation. The analyses of energy minimization, thermodynamic equilibration, RMSD, RMSF, Hydrogen Bonds, and secondary structure evaluation (DSSP) confirmed the preservation of the protein backbone after the employed methodology. Next, molecular docking was performed via DockThor between the ligands and the targets, using the structures before and after 200 ns of simulation. Among the seven phenolic compounds considered, quercetin and resveratrol stood out as the ligands with the highest affinity for BACE1. Despite the methodological challenges related to flexible docking and ensemble docking, the results reinforce the potential of these compounds as enzymatic inhibitors, validating computational drug discovery from Brazilian flora.

This work was supported by Conselho Nac. Des. Cient. Tecnológico (CNPq # 004/2024)

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 Universidade Federal de Pernambuco | (Federal University of Pernambuco)
  • 2 Federal University of Pernambuco
Track
  • 3. Drug design and delivery
Keywords
Alzheimer's Disease
BACE1 enzyme
Molecular Docking
Molecular Dynamics
Phenolic Compounds